Statin use is associated with a higher rate of sustained durable CHR in pegylated IFN-α2–treated patients with MPN. Kaplan-Meier plots showing time from initial CHR to loss of durable CHR (defined as loss of CHR across at least two consecutive clinic visits spanning ≥6 months), stratified by cytoreductive treatment and statin use. (A) Patients treated with IFN-α2 who achieved a CHR (n = 73). (B) Patients treated with HU who achieved a CHR (n = 31). w/o, without.